229 related articles for article (PubMed ID: 29504520)
1. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of FOXM1 Is a Potential Prognostic Marker in Male Breast Cancer.
Abdeljaoued S; Bettaieb I; Nasri M; Adouni O; Goucha A; El Amine O; Boussen H; Rahal K; Gamoudi A
Oncol Res Treat; 2017; 40(4):167-172. PubMed ID: 28376490
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma.
Ito T; Kohashi K; Yamada Y; Maekawa A; Kuda M; Furue M; Oda Y
Histopathology; 2016 Jul; 69(1):63-71. PubMed ID: 26619071
[TBL] [Abstract][Full Text] [Related]
7. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
8. FoxM1: Repurposing an oncogene as a biomarker.
Nandi D; Cheema PS; Jaiswal N; Nag A
Semin Cancer Biol; 2018 Oct; 52(Pt 1):74-84. PubMed ID: 28855104
[TBL] [Abstract][Full Text] [Related]
9. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
10. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.
Song BN; Chu IS
Exp Mol Med; 2018 Jan; 50(1):e418. PubMed ID: 29303511
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
Rinaldetti S; Wirtz RM; Worst TS; Eckstein M; Weiss CA; Breyer J; Otto W; Bolenz C; Hartmann A; Erben P
Oncotarget; 2017 Jul; 8(29):47595-47606. PubMed ID: 28498805
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.
Ahn H; Sim J; Abdul R; Chung MS; Paik SS; Oh YH; Park CK; Jang K
J Korean Med Sci; 2015 Apr; 30(4):390-7. PubMed ID: 25829806
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of forkhead box protein M1 (FOXM1) plays a critical role in colorectal cancer.
Zhang HG; Xu XW; Shi XP; Han BW; Li ZH; Ren WH; Chen PJ; Lou YF; Li B; Luo XY
Clin Transl Oncol; 2016 May; 18(5):527-32. PubMed ID: 26370421
[TBL] [Abstract][Full Text] [Related]
18. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.
Li L; Wu D; Yu Q; Li L; Wu P
Oncotarget; 2017 May; 8(19):32298-32308. PubMed ID: 28427178
[TBL] [Abstract][Full Text] [Related]
20. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis.
He S; Liao B; Deng Y; Su C; Tuo J; Liu J; Yao S; Xu L
BMC Cancer; 2017 Oct; 17(1):673. PubMed ID: 28978307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
